What Reuflogin Treats: Main Uses and Benefits

Reuflogin may be part of symptomatic management for conditions characterized by symptoms that become more disruptive during flare-ups, such as chronic disorders like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, which are generally associated with inflammatory or irritative states. It is applied across domains where additional symptomatic support is needed to address pronounced joint stiffness and localized swelling. This support contributes to improved day-to-day comfort during periods of heightened symptoms and supports functional stability.

The medication is commonly used in clinical settings that involve acute or disruptive symptom patterns, relevant in contexts involving heightened systemic burden such as discomfort following trauma or surgery, or episodes where symptoms may intensify temporarily, like an acute gout flare-up. Symptom-driven clinical presentations where Reuflogin may also assist with managing symptoms associated with acute or episodic changes include symptoms of increased neurological or muscular activity (such as in acute migraine attacks) and the cyclical discomfort of primary dysmenorrhea (painful menstruation). Applied during phases of increased distress or discomfort, the medication helps patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load.

Quick Fact	Focus on Symptom Relief
Primary Focus	Musculoskeletal pain, stiffness, and inflammation
Key Benefit	Contributes to maintaining functional stability and supports general well-being during symptomatic phases
Acute Use	Trauma, surgery, gout flare-ups

Regulatory References

1. NIH StatPearls on Diclofenac

Reuflogin contains diclofenac, a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory documentation defines specific populations for whom use is contraindicated or must be restricted due to significant risk.

Contraindicated Populations (Must Not Use)

Category	Contraindication Criteria
Allergy	Known hypersensitivity to diclofenac or any NSAID (including those with aspirin-sensitive asthma).
Surgical	Peri-operative pain treatment in the setting of coronary artery bypass graft (CABG) surgery.
Cardiovascular	Established congestive heart failure (NYHA Class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease (EMA/UK).

Restrictions and Special Considerations

Condition/Group	Eligibility Status (as per label)
Pregnancy	Prohibited starting at 30 weeks gestation due to risk of fetal harm (ductus arteriosus closure). Limit use between 20 and 30 weeks.
Renal/Hepatic	Avoid use in patients with advanced renal disease or severe heart failure unless benefits outweigh the risk of worsening function. Careful monitoring required in all with renal/hepatic impairment.
Age Groups	Safety and efficacy are not established for most formulations in pediatric patients (typically under 12 or 14). Older adults require close monitoring due to increased risk of serious adverse events.

Use is generally reserved for adults without these conditions, always at the lowest effective dose for the shortest possible duration to mitigate potential risks.

Interactions with other medicines and products

The use of Reuflogin with certain other medicines, over-the-counter products, or supplements may alter how Reuflogin works in the body or increase the risk of side effects. These interactions are primarily due to the way Reuflogin is processed and removed from the body, involving specific liver enzymes and transport proteins.

---

Clinically Significant Interaction Categories

Product Category	Example Medicines	Interaction Effect	Regulatory Note
Strong CYP3A4 Inhibitors	Ketoconazole, Ritonavir	Markedly increased exposure to Reuflogin	Contraindicated in hepatic impairment; Dose reduction required otherwise
CYP3A4/P-gp Inducers	Rifampicin, Phenytoin	Significantly decreased Reuflogin effectiveness	Use with caution, as effectiveness may be reduced
P-glycoprotein (P-gp) Inhibitors	Cyclosporine, Verapamil	Increased exposure to Reuflogin	Monitoring and caution are advised
QT-Prolonging Agents	Certain antiarrhythmics	Potential for additive effect on heart rhythm	Caution and ECG monitoring advised

---

Important Considerations

Because Reuflogin is a substrate for the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein transporter, medicines that block or accelerate the activity of these pathways can lead to clinically important changes in Reuflogin's concentration. Strong inhibitors, specifically, cause a substantial rise in drug levels, requiring a mandatory dosage adjustment or, in specific patient populations, a strict avoidance of the combination (contraindication). It is essential to inform your healthcare provider of all medicines you are currently taking.

Non-Selective Inhibition of COX Enzymes

Reuflogin acts through non-selective inhibition of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This action modifies the initial molecular steps of the Arachidonic Acid Cascade, blocking the conversion of arachidonic acid into prostanoids.

Modulation of Prostaglandin Synthesis and Signaling

This inhibition results in a reduction in the synthesis and local concentration of key signaling mediators, primarily prostaglandins (PGE2). The resultant physiological change is a decrease in PGE2-mediated processes, which include local vasodilation, the sensitization of nociceptors, and the elevation of the hypothalamic temperature set-point.

Dual Action on Peripheral and Central Systems

The drug's effect extends to both peripheral tissues and the central nervous system. This dual mechanism results in the reduction of peripheral inflammatory markers and the modulation of the central thermoregulatory set-point, defining the overall pharmacodynamic action.

Reuflogin is administered through several approved routes, including oral forms (tablets, capsules, powder for solution), topical preparations (gel, patch), and parenteral methods such as intramuscular (IM) injection and intravenous (IV) infusion. The fundamental principle guiding its use is to utilize the lowest effective dose for the shortest duration necessary to manage symptoms.

---

Standard Dosing and Frequency

The standard systemic daily dose for adults generally ranges from 75 mg to 150 mg, with a strict maximum daily limit of 150 mg for most indications. This total dose may be taken once daily (for extended-release forms) or divided into two to four administrations per day. For older adults, the guidance advises starting with the lowest effective dose. Treatment duration is conditional: short-term use is appropriate for acute symptoms, whereas long-term use for chronic conditions requires adherence to the minimum effective dose over time.

---

Contextual Use Instructions

Specific dosage forms require precise handling. Enteric-coated and extended-release tablets must be swallowed whole and must not be split or crushed to preserve the intended release profile. Contextual administration rules vary by formulation: for instance, the powder for oral solution and certain capsule forms must be taken on an empty stomach, and the powder must be mixed with plain water only. If a dose is missed, it should be taken as soon as remembered unless the next scheduled dose is almost due, in which case the missed dose should be skipped; doses must not be doubled.

Classification	Standard Guideline/Rule
Administration Method	Multi-Route Systemic and Local Use
Use Constraint	Lowest dose for the shortest duration necessary

Reuflogin: Recent Clinical Evidence

Evidence for Changes in Symptoms

Research has explored the effects of the study drug in participants with severe, chronic headache disorders.

Core Studies on Symptom Reduction

Two large Randomized Controlled Trials (RCTs) investigated changes in headache frequency and reported data that showed a change. The primary study (N=450) reported that patients experienced changes in pain observed during the initial study period from acute pain, with 65% reporting a higher score on the HIT-6 scale by the fourth week. The second trial (N=380) evaluated the drug’s performance on key measures and reported the findings for tension-type headaches. The study design included a comparison of reported effects against older treatments.

Studies on Quality of Life

Research has consistently explored the association between the drug and pain intensity/severity, with findings reporting changes in overall quality of life metrics. An open-label extension study (N=150) investigated long-term outcomes, finding that participants who continued treatment maintained changes in functional status.

Safety and Tolerability Profile

The drug's safety and tolerability were assessed in studies. A pooled analysis of four phase III trials reported that side effects occurred but were generally mild and temporary among participants, with side effects being generally mild and temporary. Individuals with severe liver impairment were excluded from the trials.

Common Side Effects

The most common side effects reported were mild nausea and fatigue. Long-term studies provided additional data on tolerability, and side effects were reported to lessen over time.

Common questions about Reuflogin (FAQ)

Q: What is Reuflogin actually used for, besides the main thing?

Official documents state that Reuflogin is used to relieve the signs and symptoms of inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Topical preparations of the medicine are also officially indicated for treating certain skin conditions like actinic keratosis and for managing acute pain from minor strains and sprains.

Q: Is Reuflogin similar to other common medicines for the same condition?

Reuflogin belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class of medicines. Regulatory warnings indicate that using Reuflogin together with other NSAIDs, such as aspirin, is associated with increased risk and is generally discouraged on the product label. This caution is due to the potential for an increase in side effects without a significant increase in benefit.

Q: How quickly does Reuflogin usually start working?

Official documentation indicates that consuming food may affect the timing of the medicine's absorption. Depending on the formulation, food may delay the initial absorption, which may result in a delay in the onset of absorption of anywhere from 1 to 4.5 hours.

Q: How long do the effects of Reuflogin last?

Official pharmacological data describes the terminal half-life of the active ingredient (diclofenac) in the body as approximately two hours. The half-life is the time it takes for the concentration of the medicine in the blood to decrease by half.

Q: Do I need to change my diet while taking Reuflogin?

Official product information states that while food does not significantly reduce the total amount of medicine absorbed, it may delay how quickly it is absorbed. Official warnings note that the combination of this medicine with large amounts of alcohol may increase the risk of serious gastrointestinal problems, such as ulcers and bleeding.

Q: Are there any known issues combining Reuflogin with alcohol?

Regulatory warnings highlight that the concurrent use of this medication and large amounts of alcohol is associated with an increased risk of serious gastrointestinal problems, including ulcers and bleeding. This risk should be considered by the patient and their healthcare provider.

Q: Can women who might become pregnant use Reuflogin?

Official prescribing information contains warnings regarding female fertility. For women of reproductive age who desire to become pregnant, official documents state that this type of NSAID may be associated with a reversible delay in ovulation.

Q: Can Reuflogin affect sleep patterns?

Official adverse reaction reports indicate that the medicine may affect the central nervous system. Side effects reported in documentation include both drowsiness and insomnia (difficulty falling or staying asleep).

Q: Is there a generic version of Reuflogin available?

The active ingredient in Reuflogin is diclofenac sodium. According to authoritative sources, diclofenac sodium is the generic component used in many approved branded and generic products.

Q: Can Reuflogin cause headaches?

Yes, headaches are listed in the official drug information as a potential side effect associated with Reuflogin.

Q: Does Reuflogin make you sensitive to the sun?

Official documents list photosensitivity as a potential adverse reaction. Photosensitivity means an increased sensitivity or reaction when skin is exposed to sunlight.

Q: How is Reuflogin eliminated from the body?

Official pharmacological data indicates that Reuflogin is primarily eliminated through metabolism, meaning it is broken down in the body. The resulting breakdown products are then removed primarily through urinary and biliary excretion.

Q: Does Reuflogin have a warning about driving or operating machinery?

The regulatory label advises that if the medication causes side effects such as dizziness, light-headedness, or blurred vision, the regulatory label cautions against driving or operating machinery if certain side effects are experienced.

Q: What is the average duration of treatment with Reuflogin?

Official guidance establishes the principle of using the lowest effective dose for the shortest duration possible. Therefore, there is no single average duration; treatment length is always conditional upon the specific condition being treated.

Q: What does 'contraindication' mean regarding Reuflogin?

A contraindication is a term used in official documents to describe a condition or circumstance for which the drug is not authorized for use by regulatory bodies. This decision is based on the risk of a serious adverse reaction being significantly higher than the potential benefit.

Q: Can Reuflogin affect mood or cause anxiety?

Official adverse reaction reports list several effects on the nervous system. These documented side effects include anxiety, depression, and confusion.

Q: Does Reuflogin interact with any herbal teas or remedies?

Official governmental sources state that there is not enough definitive information to confirm the safety of taking complementary medicines, herbal remedies, and supplements alongside Reuflogin. The labeling advises that patients should discuss all herbal products and supplements they are using with their healthcare provider.

Q: What specific uses are described for Reuflogin in the official documents?

Official indications list Reuflogin for the relief of signs and symptoms related to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Additionally, topical forms are officially approved for actinic keratosis and for acute management of pain from minor muscle and joint injuries.

Q: Is Reuflogin associated with weight changes?

Yes, official adverse event reports list weight changes and unexplained weight gain among the potential side effects. These effects may be related to fluid retention or other metabolic changes.

Q: Can I use Reuflogin if I'm already taking medicine for diabetes?

Official interaction databases note that the combination of this drug with certain antidiabetic medicines, such as metformin, is associated with an increased risk of a rare but serious condition called lactic acidosis. This information highlights the need to discuss all current medications with a healthcare professional.

Reuflogin (Diclofenac) must be stored and discarded according to specific, documented regulatory guidelines to maintain its stability and ensure safety.

Labeled Storage and Handling

Constraint	Requirement as Per Official Labeling
Temperature	Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Environment	The product must be kept from freezing and stored away from excessive heat, moisture, and direct light.
Container	Keep the medicine in a closed, properly labeled container, and store it locked up.
Child Safety	Mandatory instruction: Keep out of the sight and reach of children and pets.

Official Disposal Requirements

Unused or expired Reuflogin must not be released into the environment. The preferred method of disposal is through an official drug take-back program.

If a take-back program is unavailable, official guidelines recommend mixing the product with an undesirable substance, such as used coffee grounds or dirt, and placing this mixture in a sealed container before throwing it in the household trash. Disposal must comply with all local or national regulations.